Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
نویسندگان
- Philip M Bath
- Lisa J Woodhouse
- Jason P Appleton
- Maia Beridze
- Hanne Christensen
- Robert A Dineen
- Lelia Duley
- Timothy J England
- Katie Flaherty
- Diane Havard
- Stan Heptinstall
- Marilyn James
- Kailash Krishnan
- Hugh S Markus
- Alan A Montgomery
- Stuart J Pocock
- Marc Randall
- Annemarei Ranta
- Thompson G Robinson
- Polly Scutt
- Graham S Venables
- Nikola Sprigg
- L M Christensen
- L Bentsen
- C Krarup Hansen
- T T Thomsen
- C Kruuse
- H H Jensen
- S S Hansen
- V Petrovic
- N Beridze
- N Kakabadze
- T Kherkheulidze
- D Kakabadze
- I Toidze
- N Lobjanidze
- N Akiashvili
- A Tevdoradze
- N Khizanishvili
- T Tsanava
- R Taylor
- I Iniesta
- J Kok
- J Duignan
- M Funnell
- P Cariga
- M Rodriguez
- I J Watson
- S Tennant
- M Macleod
- J Furnace
- H Gow
- J Irvine
- A Joyson
- S Nelson
- V Taylor
- M Smith
- R Bellfield
- B Hairsine
- R Davies
- A Dodd
- J Corrigan
- M Doherty
- A Ahmed
- C Denniss
- S Johnson-Holland
- K A Kay
- R Icart Palau
- G Auld
- P Daboo
- R Erande
- G Grimwood
- D Hove
- L Howaniec
- O Redjep
- R Rangasamay
- G Butt
- D Sandler
- J Reddan
- S Stafford
- J McIlmoyle
- S Maguire
- P Murphy
- J Chambers
- L Guthrie
- M Osborn
- A Steele
- M Burn
- A Benford
- A Misra
- D Hilton
- E O'Brien
- E Amis
- S Finlay
- J Mitchell
- O Geraghty
- K Harvey
- B Hazel
- S Mashate
- P Wilding
- M Sajid
- M Ball
- R Gascoyne
- R Sivakumar
- A Wright
- K Chatterjee
- S Booth
- H Eccleson
- C Kelly
- S Leason
- C Perkins
- D Bruce
- E Brown
- S Clayton
- M Garside
- G Rogers
- E Lawrence
- S Mahmood
- C Watchurst
- D Chadha
- L Glover
- L Holford
- K Smith
- D Walstow
- R Williams
- L O'Shea
- J Goodsell
- C Athulathmudali
- E Barbon
- R Namushi
- P Jacob
- L Johnson
- D Morse
- C McGhee
- O Speirs
- S Atkinson
- A Peacocke
- P Langhorne
- R Graham
- F Wright
- C McAlpine
- A Ravindrane
- M Bajoriene
- L Matter
- S Windebank
- E Giallombardo
- D Dellafera
- C Eglinton
- J Wilson
- D Broughton
- K Chapman
- L Dixon
- M Zaidi
- K Ayes
- J Kessell
- D Manawadu
- O Adegbaju
- J Aeron-Thomas
- K Anderson
- A Brigden
- E Cattermole
- J Good
- S Hassan
- E Khoromana
- L Lee-Carbon
- K Marks
- E Mckenzie
- N Sikondari
- M Cooper
- K Whysall
- I Wynter
- J Bamford
- A Hassan
- P Wanklyn
- M Kambafwile
- L Makawa
- D Waugh
- E Veraque
- MGG Soliman
- S Arif
- R Brown
- S Butler
- C Hewitt
- J Hindle
- A Pusalkar
- H Beadle
- K Chan
- M Siddiqui
- P Dangri
- S Buddha
- A Asokanathan
- A Mistri
- D Eveson
- K Musarrat
- L Manning
- S Anand
- P Christian
- S Khan
- C Patel
- M Sein
- J Banns
- E Gibson
- T Gordon
- Y Gruenbeck
- S Wong
- P Datta
- G Bateman
- L Jackson
- A Needle
- Y Duodu
- R Oliver
- C Padilla-Harris
- M Barber
- D Esson
- F Brodie
- C McInnes
- K Fotherby
- D Butler
- D Morgan
- K Preece
- A Willberry
- M Dent
- F Hammonds
- J Hunt
- C Vernon
- D O'Kane
- F Faola
- P Lai
- J O'Callaghan
- C Smith
- C Price
- R Lakey
- V Riddell
- A Smith
- G Storey
- S Munshi
- A Buck
- J Clarke
- N Gilzeane
- M Godfrey
- R Keshvara
- C Richardson
- J Roffe
- L Ryan
- F Shelton
- W Sunman
- A Tittle
- J Tomlinson
- K Whittamore
- G Wilkes
- P Owusu-Agyei
- N Temple
- D Mangion
- A Hardwick
- K Netherton
- A Mohd Nor
- B Hyams
- S Norman
- N Persad
- S Ragab
- C Dickson
- J Dube
- E Jinks
- K Knops
- B Wadams
- K Ali
- J Gaylard
- G Spurling
- L Sztriha
- T Ajao
- M Alao
- F K Chan
- P Webster
- P Howard
- T J Dobson
- L Hyatt
- D Sims
- J Cunningham
- B Esisi
- T Cassidy
- M Bokhari
- B McClelland
- B Mokoena
- G Gunathilagan
- S Jones
- M Reader
- G Thomas
- S Tilby
- P Findlay
- F Barrett
- F Leslie
- S Ross
- I Shread
- J Okwera
- J Howe
- F Harrington
- G Courtauld
- C Schofield
- R Donnelly
- M Maddula
- J Scott
- J Beavan
- K Muhidden
- I Memon
- M Clarke
- A Hedstrom
- L Mills
- A Hemsley
- A Bowring
- L Boxall
- H Kingwell
- S Keenan
- C Roughan
- A Manoj
- P Cox
- G Fletcher
- P Lopez
- H Emsley
- B Gregary
- A McLoughlin
- S Raj
- C Roffe
- N Abano
- A Barry
- A Butler
- R Carpio
- K Castro
- K Finney
- S Gomm
- J Hiden
- J Grocott
- S Lyjko
- H Maguire
- A Remegoso
- R Sanyal
- S Stevens
- I Natarajan
- J Chembala
- G Muddegowda
- A Warusevitane
- A Blight
- O Balazikova
- C Lawlor
- L Shaw
- D Button
- D Howcroft
- S Lucas
- B Madigan
- S McCann
- A Dixit
- A Barkat
- J Davis
- M Fawcett
- L Finlay
- H Guy
- C Hays
- V Hogg
- E Horsley
- C Hubbuck
- C Pringle
- C Stevenson
- K Storey
- T Thompson
- S Woodward
- A Banerjee
- C Allcock
- S Merotra
- C Douglass
- E Campbell
- R Jarapa
- M Johnes
- C Keaveney
- T Marsden
- Z Naing
- J Perez
- K Shaw
- T Black
- A Anthony
- C Clarke
- J Paterson
- K Deighton
- E Temlett
- C Blank
- C Doyle
- S Duty
- K Gill
- K Harkness
- C Kamara
- E Richards
- K Elfandi
- P Guyler
- P Harman
- C Khuoge
- S Kunhunny
- S Tysoe
- B Moynihan
- T Adedoyin
- N Chopra
- N Dayal
- R Ghatala
- N Jeyaraj
- I Jones
- F Kennedy
- L Kerin
- N Khanom
- S Lewis
- S Maheswaran
- L Montague
- M Niemierko
- J O'Reilly
- S Trippier
- F Watson
- P Wilkinson
- E Young
- K Dizayee
- H Cochrane
- J O'Connell
- L Mokoena
- E Osborne
- A Nair
- J Greig
- C Jenkins
- J Powell
- F Price
- M Chowdhury
- S Brixey
- L Hunt
- N Rands
- G Rose
- S Stoddart
- M Srinivasan
- N Motherwell
- R Shekhar
- T Fuller
- A Lankester
- P Lingwood
- C Rankin
- H Webb
- B Jupp
- J Bell
- G Hann
- B Longland
- C Ovington
- B Bhaskaran
- G Ayres
- C Bailey
- H Bearne
- J Buxton
- P Fitzell
- C Hilaire
- D Kelly
- S Szabo
- D Tomlin
- E Gamble
- B Charles
- R Kumar
- T Fluskey
- Z Mellor
- J Peters
- V Sutton
- A Kenton
- I Martin
- S Nyabadza
- S Ghosh
- M Henry
- B Kumar
- C Ambulo
- S Crawford
- T Nozedar
- M Platton
- V Cvoro
- M Couser
- K McCormick
- D Wilkinson
- K Javaid
- S Hurdowar
- T Attygalle
- S Sundayi
- O Orugun
- H Crowther
- R Jolly
- U Poultney
- A Azim
- M Krasinska-Chavez
- J White
- N Sengupta
- J Margalef
- M G Metiu
- S Meenakshisundaram
- S Dealing
- D Hargroves
- E Beranova
- L Cowie
- H Rudenko
- A Thomson
- A Verrion
- K Rashed
- S Board
- C Buckley
- D Hayward
چکیده
BACKGROUND Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) with that of guideline-based antiplatelet therapy. METHODS We did an international, prospective, randomised, open-label, blinded-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) within 48 h of onset. Participants were assigned in a 1:1 ratio using computer randomisation to receive loading doses and then 30 days of intensive antiplatelet therapy (combined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily) or guideline-based therapy (comprising either clopidogrel alone or combined aspirin and dipyridamole). Randomisation was stratified by country and index event, and minimised with prognostic baseline factors, medication use, time to randomisation, stroke-related factors, and thrombolysis. The ordinal primary outcome was the combined incidence and severity of any recurrent stroke (ischaemic or haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days, as assessed by central telephone follow-up with masking to treatment assignment, and analysed by intention to treat. This trial is registered with the ISRCTN registry, number ISRCTN47823388. FINDINGS 3096 participants (1556 in the intensive antiplatelet therapy group, 1540 in the guideline antiplatelet therapy group) were recruited from 106 hospitals in four countries between April 7, 2009, and March 18, 2016. The trial was stopped early on the recommendation of the data monitoring committee. The incidence and severity of recurrent stroke or TIA did not differ between intensive and guideline therapy (93 [6%] participants vs 105 [7%]; adjusted common odds ratio [cOR] 0·90, 95% CI 0·67-1·20, p=0·47). By contrast, intensive antiplatelet therapy was associated with more, and more severe, bleeding (adjusted cOR 2·54, 95% CI 2·05-3·16, p<0·0001). INTERPRETATION Among patients with recent cerebral ischaemia, intensive antiplatelet therapy did not reduce the incidence and severity of recurrent stroke or TIA, but did significantly increase the risk of major bleeding. Triple antiplatelet therapy should not be used in routine clinical practice. FUNDING National Institutes of Health Research Health Technology Assessment Programme, British Heart Foundation.
منابع مشابه
Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
BACKGROUND AND PURPOSE The effects of alternative antiplatelet agents such as clopidogrel and dipyridamole have been studied in clinical trials and heavily marketed. Because public data on their usage are limited, we examined trends in their prescription after stroke and transient ischemic attack to assess the impact of marketing and trial results. METHODS Between 2001 and 2005, 85 US hospita...
متن کاملA Randomised Controlled Trial of Triple Antiplatelet Therapy (Aspirin, Clopidogrel and Dipyridamole) in the Secondary Prevention of Stroke: Safety, Tolerability and Feasibility
BACKGROUND Aspirin, dipyridamole and clopidogrel are effective in secondary vascular prevention. Combination therapy with three antiplatelet agents might maximise the benefit of antiplatelet treatment in the secondary prevention of ischaemic stroke. METHODOLOGY/PRINCIPAL FINDINGS A randomised, parallel group, observer-blinded phase II trial compared the combination of aspirin, clopidogrel and...
متن کاملStatistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
RATIONALE Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke. Importantly, the risk of recurrence is highest immediately after the index event while antiplatelets cause bleeding. AIMS AND/OR HYPOTHESIS The 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial is testing whether short-...
متن کاملSecondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
The prevention of secondary vascular events is of paramount importance in patients with a history of stroke or transient ischemic attack (TIA). Most cardiologists are aware of the benefits of clopidogrel plus aspirin versus those of other antiplatelet regimens in patients with acute coronary syndrome. Using a representative post-stroke patient as an example, this article reviews data evaluating...
متن کاملCombination Therapy With Clopidogrel and Aspirin Can the CURE Results Be Extrapolated to Cerebrovascular Patients?
Several antiplatelet agents with different mechanisms of action are currently available for secondary prevention of ischemic stroke. When used as a single agent, the efficacy of antiplatelet therapy is modest. Aspirin is the best-studied and most widely used antiplatelet agent for stroke prevention; however, it provides only an approximately 15% relative risk reduction for secondary prevention ...
متن کاملCombination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients?
Several antiplatelet agents with different mechanisms of action are currently available for secondary prevention of ischemic stroke. When used as a single agent, the efficacy of antiplatelet therapy is modest. Aspirin is the best-studied and most widely used antiplatelet agent for stroke prevention; however, it provides only an approximately 15% relative risk reduction for secondary prevention ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 391 شماره
صفحات -
تاریخ انتشار 2018